Somatization disorder

Summary

Somatization disorder (MONDO:0001830) is a disease and 12 clinical trials. A subtype of somatoform disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	somatization disorder
Mondo ID	MONDO:0001830
DOID	DOID:13918
ICD-10-CM	F45.0
SNOMED CT	397923000
UMLS	C0520482
MedGen	99241
Is cancer (heuristic)	no

Also known as: Briquet’s disorder

Disease family

This is a subtype of somatoform disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › somatoform disorder › somatization disorder

Related subtypes (5): body dysmorphic disorder, neurocirculatory asthenia, hypochondriasis, conversion disorder, physiological malfunction arising from mental factor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01903096	PHASE4	COMPLETED	Treating Emotional Disorders in Primary Care With Psychological Techniques
NCT00132197	PHASE2/PHASE3	COMPLETED	Treatment of Patients With Longstanding Unexplained Health Complaints
NCT00149760	PHASE2	COMPLETED	Effectiveness of Cognitive-Affective Behavior Therapy for the Treatment of Somatization Disorder
NCT01187797	PHASE1/PHASE2	COMPLETED	Effects of Emotional Stimulation on the Stress Levels of Healthy Persons
NCT00497185	Not specified	COMPLETED	Mindfulness-based Cognitive Therapy for Patients With Functional Disorders
NCT01158430	Not specified	COMPLETED	Acceptance and Commitment Group Therapy (ACT) for Patients With Health Anxiety
NCT02346071	Not specified	COMPLETED	Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes
NCT03321409	Not specified	UNKNOWN	Assessment of Somatic Symptom Burden
NCT03513185	Not specified	COMPLETED	Assessment of SSD in Outpatients Using SSS-CN
NCT04815863	Not specified	COMPLETED	Assessment of Somatic Symptom in Chinese Community-Dwelling People
NCT04870476	Not specified	WITHDRAWN	Feasibility and Acceptability of the Internet-delivered Treatment One Step at the Time for Bodily Distress Syndrome
NCT07292064	Not specified	COMPLETED	Type D Personality, Somatization and Perceived Social Support in Temporomandibular Joint Disorders